Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder
The DOI matches its Crossref record.
Abstract
INTRODUCTION: Two small, double-blind, placebo-controlled, single-dose, crossover studies found dextroamphetamine (d-amphetamine) 30 mg clearly superior to placebo in relieving symptoms of obsessive-compulsive disorder (OCD). We conducted a 5-week, double-blind, caffeine-controlled study to test the hypothesis that d-amphetamine, added after an adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) trial, would be more effective than caffeine in reducing residual OCD symptoms of moderate or greater severity. METHOD: Between August 2006 and February 2008, we enrolled adults with DSM-IV OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >or= 20 after >or= 12 weeks of adequate treatment with an SSRI or SNRI. Subjects were randomly assigned to double-blind d-amphetamine 30 mg/d or caffeine 300 mg/d added to their SSRI/SNRI and other medications. Responders (first week mean Y-BOCS score decrease of >or= 20%) entered the study's 4-week double-blind extension phase. RESULTS: We enrolled 24 subjects, 11 women and 13 men, with a mean (SD) age of 40 (13.2) years and mean baseline Y-BOCS scores of 26.5 (4.1) for the d-amphetamine group (n = 12) and 29.1 (4.0) for the caffeine group (n = 12). At the end of week 1, 6 of 12 d-amphetamine subjects (50%) and 7 of 12 caffeine subjects (58%) were responders. At week 5, the responders' mean Y-BOCS score decreases were, for the d-amphetamine group (last observation carried forward), 48% (range, 20%-80%); and, for the caffeine group, 55% (range, 27%-89%). Obsessive-compulsive disorder and depression improvement were independent. The double-blind remained intact. No subject discontinued the study due to side effects. CONCLUSIONS: Larger, double-blind, placebo-controlled trials of both d-amphetamine and caffeine augmentation are needed in OCD subjects inadequately responsive to adequate doses of an SSRI or SNRI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00363298.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In OCD patients, alertness has been associated with the disorder’s phenotype [26], [27].”
From The rollercoaster of obsessive-compulsive disorder: How chronotype and time of day affect behavioral inhibition in adults with OCD (2025) · cites this paper as [26]
In the citing paper
“although three small clinical trials have shown evidence that the related drug, dexamphetamine, can be effective in OCD (Insel et al. 1983; Joffe et al. 1991; Koran et al. 2009).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Koran et al. 2009
Citations
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“The findings of a randomised comparator-controlled trial of dextroamphetamine or caffeine augmentation of SSRI or SNRI antidepressants suggest both compounds were beneficial in reducing symptom severity [II] (Koran et al., 2009).”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Caffeine, Mental Health, and Psychiatric Disorders
Lara, D. R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1378 · Cited by 233
“In contrast, a recent randomized controlled trial showed that caffeine led to clinical response in 7 out of 12 patients with treatment-resistant obsessive compulsive disorder (OCD) and a 55% reduction of symptom score in these responders, which was comparable to d-amphetamine [42].”
BackgroundFontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
“Finally, case reports,([100]) small case series([101]) and a double-blind, 4-week study comparing amphetamine salts with caffeine([102]) suggest that amphetamine salts may help OCD patients, particularly those with hoarding as a symptom.”
BackgroundPharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
“Both dextroamphetamine and caffeine led to significant improvements in refractory patients over 5 weeks [60].”
Background
Metadata
- Authors
- Koran, L. M., Aboujaoude, E., & Gamel, N. N.
- Affiliations
- Stanford University (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-06-30
- Volume
- 70
- Issue
- 11
- Pages
- 1530-1535
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2081132633
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 8 · 2013: 5 · 2012: 3
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- obsessive-compulsive disorder, d-amphetamine, treatment-resistant OCD, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, Yale-Brown Obsessive Compulsive Scale, adverse effects, treatment discontinuation
- MeSH terms
- Adult, Caffeine, Dextroamphetamine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Longitudinal Studies, Male, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Neurotransmitter Uptake Inhibitors, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. https://app.cochat.ai/papers/10.4088/jcp.08m04605
- The paper
- Koran, L. M., Aboujaoude, E., & Gamel, N. N. (2009). Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.08m04605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.